- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 164803, 10 pages
β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells
1The Department of Pediatrics, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA
2The Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA
3The Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
4Division Hematology/Oncology, Department of Pediatrics, The Children’s Hospital at Montefiore, Room 300, Rosenthal Building, 3415 Bainbridge Avenue, Bronx, NY 10467, USA
5Oncology Section, The Department of Orthopedics Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100037, China
6The Department of Orthopedics Surgery, College of Medicine, Kosin University Gospel Hospital, Busan 602-702, Republic of Korea
7Department of Pediatrics and Molecular Pharmacology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA
8Division of Hematology/Oncology, Department of Pediatrics, The Children's Hospital at Montefiore, Room 300, Rosenthal Building, 3415 Bainbridge Avenue, Bronx, NY 10467, USA
Received 5 July 2012; Revised 23 September 2012; Accepted 23 September 2012
Academic Editor: H. Gelderblom
Copyright © 2012 Sajida Piperdi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009.
- G. Ottaviani and N. Jaffe, “The epidemiology of osteosarcoma,” Cancer Treatment and Research, vol. 152, pp. 3–13, 2009.
- R. Gorlick BS, L. Teot, J. Meyer, L. Randall, and N. Marina, “Osteosarcoma: biology, diagnosis, treatment and remaining challengings,” in Principles and Practice of Pediatric Oncology, P. A. Pizzo and D. G. Poplack, Eds., pp. 1015–1044, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2011.
- C. D. M. Fletcher, K. K. Unni, and F. Mertens, Eds., Pathology and Genetics of Tumors of Soft Tissue and Bone, WHO Classification of Tumors, IARC Press, Lyon, France, 2002.
- M. Kansara and D. M. Thomas, “Molecular pathogenesis of osteosarcoma,” DNA and Cell Biology, vol. 26, no. 1, pp. 1–18, 2007.
- A. B. Mohseny and P. C. W. Hogendoorn, “Concise review: mesenchymal tumors: when stem cells go mad,” Stem Cells, vol. 29, no. 3, pp. 397–403, 2011.
- R. Ricafort and R. Gorlick, “Molecularly targeted therapy in osteosarcoma,” in Molecularly Targeted Therapy for Childhood Cancer, R. Arceci and P. J. Houghton, Eds., pp. 459–498, Springer, New York, NY, USA, 2010.
- T. Reya and H. Clevers, “Wnt signalling in stem cells and cancer,” Nature, vol. 434, no. 7035, pp. 843–850, 2005.
- N. Barker and H. C. Catenins, “Wnt signaling and cancer,” Bioessays, vol. 22, no. 11, pp. 961–965, 2000.
- K. M. Cadigan and R. Nusse, “Wnt signaling: a common theme in animal development,” Genes and Development, vol. 11, no. 24, pp. 3286–3305, 1997.
- J. Deng, S. A. Miller, H. Y. Wang et al., “β-catenin interacts with and inhibits NF-κB in human colon and breast cancer,” Cancer Cell, vol. 2, no. 4, pp. 323–334, 2002.
- Y. W. Qiang, Y. Endo, J. S. Rubin, and S. Rudikoff, “Wnt signaling in B-cell neoplasia,” Oncogene, vol. 22, no. 10, pp. 1536–1545, 2003.
- A. T. Weeraratna, Y. Jiang, G. Hostetter et al., “Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma,” Cancer Cell, vol. 1, no. 3, pp. 279–288, 2002.
- R. C. Haydon, A. Deyrup, A. Ishikawa et al., “Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma,” International Journal of Cancer, vol. 102, no. 4, pp. 338–342, 2002.
- D. Mandal, A. Srivastava, E. Mahlum et al., “Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma,” Gene, vol. 386, no. 1-2, pp. 131–138, 2007.
- B. H. Hoang, T. Kubo, J. H. Healey et al., “Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma,” International Journal of Cancer, vol. 109, no. 1, pp. 106–111, 2004.
- M. Kansara, M. Tsang, L. Kodjabachian et al., “Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice,” Journal of Clinical Investigation, vol. 119, no. 4, pp. 837–851, 2009.
- K. Chen, S. Fallen, H. O. Abaan et al., “Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival,” Pediatric Blood and Cancer, vol. 51, no. 3, pp. 349–355, 2008.
- M. Enomoto, S. Hayakawa, S. Itsukushima et al., “Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling,” Oncogene, vol. 28, no. 36, pp. 3197–3208, 2009.
- B. H. Hoang, T. Kubo, J. H. Healey et al., “Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway,” Cancer Research, vol. 64, no. 8, pp. 2734–2739, 2004.
- E. M. Rubin, Y. Guo, K. Tu, J. Xie, X. Zi, and B. H. Hoang, “Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma,” Molecular Cancer Therapeutics, vol. 9, no. 3, pp. 731–741, 2010.
- W. C. Hahn, C. M. Counter, A. S. Lundberg, R. L. Beijersbergen, M. W. Brooks, and R. A. Weinberg, “Creation of human tumour cells with defined genetic elements,” Nature, vol. 400, no. 6743, pp. 464–468, 1999.
- N. Li, R. Yang, W. Zhang, H. Dorfman, P. Rao, and R. Gorlick, “Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential,” Cancer, vol. 115, no. 20, pp. 4795–4806, 2009.
- M. Miura, Y. Miura, H. M. Padilla-Nash et al., “Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation,” Stem Cells, vol. 24, no. 4, pp. 1095–1103, 2006.
- J. Tolar, A. J. Nauta, M. J. Osborn et al., “Sarcoma derived from cultured mesenchymal stem cells,” Stem Cells, vol. 25, no. 2, pp. 371–379, 2007.
- A. B. Mohseny, K. Szuhai, S. Romeo et al., “Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2,” Journal of Pathology, vol. 219, no. 3, pp. 294–305, 2009.
- V. S. Spiegelman, T. J. Slaga, M. Pagano, T. Minamoto, Z. Ronai, and S. Y. Fuchs, “Wnt/β-catenin signaling induces the expression and activity of βTrCP ubiquitin ligase receptor,” Molecular Cell, vol. 5, no. 5, pp. 877–882, 2000.
- D. M. Thomas, “Wnts, bone and cancer,” Journal of Pathology, vol. 220, no. 1, pp. 1–4, 2010.
- Y. Guo, E. M. Rubin, J. Xie, X. Zi, and B. H. Hoang, “Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2039–2045, 2008.
- Y. Guo, X. Zi, Z. Koontz et al., “Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells,” Journal of Orthopaedic Research, vol. 25, no. 7, pp. 964–971, 2007.
- P. C. Leow, Q. Tian, Z. Y. Ong, Z. Yang, and P. L. R. Ee, “Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells,” Investigational New Drugs, vol. 28, no. 6, pp. 766–782, 2010.
- N. Lee, A. J. Smolarz, S. Olson et al., “A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies,” British Journal of Cancer, vol. 97, no. 11, pp. 1552–1559, 2007.
- K. Iwaya, H. Ogawa, M. Kuroda, M. Izumi, T. Ishida, and K. Mukai, “Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis,” Clinical and Experimental Metastasis, vol. 20, no. 6, pp. 525–529, 2003.
- T. J. Stein, K. E. Holmes, A. Muthuswamy, V. Thompson, and M. K. Huelsmeyer, “Characterization of β-catenin expression in canine osteosarcoma,” Veterinary and Comparative Oncology, vol. 9, no. 1, pp. 65–73, 2011.
- A. M. Cleton-Jansen, J. K. Anninga, I. H. Briaire-de Bruijn et al., “Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.,” British Journal of Cancer, vol. 101, no. 12, article 2064, 2009.
- Y. Cai, A. B. Mohseny, M. Karperien, P. C. W. Hogendoorn, G. Zhou, and A. M. Cleton-Jansen, “Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma,” Journal of Pathology, vol. 220, no. 1, pp. 24–33, 2010.
- Y. Gong, R. B. Slee, N. Fukai, et al., “LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development,” Cell, vol. 107, no. 4, pp. 513–523, 2001.
- L. M. Boyden, J. Mao, J. Belsky et al., “High bone density due to a mutation in LDL-receptor-related protein 5,” The New England Journal of Medicine, vol. 346, no. 20, pp. 1513–1521, 2002.
- L. van Wesenbeeck, E. Cleiren, J. Gram et al., “Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density,” American Journal of Human Genetics, vol. 72, no. 3, pp. 763–771, 2003.
- N. Tang, W. X. Song, J. Luo, R. C. Haydon, and T. C. He, “Osteosarcoma development and stem cell differentiation,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2114–2130, 2008.